CN1256137C - 一种治疗肺结核病的中药 - Google Patents
一种治疗肺结核病的中药 Download PDFInfo
- Publication number
- CN1256137C CN1256137C CNB031108938A CN03110893A CN1256137C CN 1256137 C CN1256137 C CN 1256137C CN B031108938 A CNB031108938 A CN B031108938A CN 03110893 A CN03110893 A CN 03110893A CN 1256137 C CN1256137 C CN 1256137C
- Authority
- CN
- China
- Prior art keywords
- effect
- medicine
- chinese medicine
- tuberculosis
- pulmonary tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 208000008128 pulmonary tuberculosis Diseases 0.000 title claims abstract description 14
- 239000002994 raw material Substances 0.000 claims description 6
- 241000283956 Manis Species 0.000 claims description 4
- 108010052008 colla corii asini Proteins 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 241001523579 Ostrea Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004072 lung Anatomy 0.000 abstract description 11
- 201000008827 tuberculosis Diseases 0.000 abstract description 6
- 206010011224 Cough Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 230000002147 killing effect Effects 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 241001313855 Bletilla Species 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 241001671204 Stemona Species 0.000 abstract 1
- 241000607479 Yersinia pestis Species 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000002308 calcification Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 208000030208 low-grade fever Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- FVVDKUPCWXUVNP-UHFFFAOYSA-M Aminosalicylate sodium anhydrous Chemical compound [Na+].NC1=CC=C(C([O-])=O)C(O)=C1 FVVDKUPCWXUVNP-UHFFFAOYSA-M 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229940046927 sodium aminosalicylate Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种治疗肺结核病的中药,是由白芨、百部、牡蛎、贝母、阿胶、甲珠原料药配伍而成,具有治痨杀虫、滋阴降火、润肺止咳、益气健脾、清热化痰、生血、止血之功效,无毒无副作用及不良反应,对人体各脏器、肝、脑、肾、中枢神经无损害,治疗时间短,见效快,对肺部各型结核病治愈率高,愈后不易复发。通过临床试验治疗肺结核患者共一千多例,治愈率高,效果好,对西药有抗药性的病人服用效果更好,总有效率达99%,显效率达98%,治愈率99%。
Description
技术领域:
本发明属于中药制剂,尤其涉及的是一种治疗肺结核病的中药。
背景技术:
肺部结核病是一种慢性病、多发病、常见病,中医称肺部痨病,是因痨虫浸入肺组织导致的一种肺部疾病,西医称为结核杆菌浸入肺部组织引起的一种疾病。
目前,在临床医学中,治疗肺部结核病大都采用西药四联用药法来抑制杀灭结核杆菌达到治疗的目的。常用的口服药物有异烟肼、利福平、乙胺丁醇、吡嗪酰胺,静脉滴注对氨基水杨酸钠,肌注链霉素,连续用药4-6个月以后改为两种用药,全程用药1-2年。虽然对结核杆菌有抑制杀灭作用,但疗程长、见效慢、治愈率低,而且毒副作用大,长期用药对消化系统、肝、脑、肾、中枢神经均有不同程度损害。
发明内容:
本发明所要解决的技术问题是提供一种不用肌注静点,只需口服的纯中药制剂,无毒、副作用,无不良反应,对肝、脑、肾、中枢神经无损害。易服、易吸收、疗程短、见效快、治愈率高,治愈后不易复发。
本发明所选原料药为(按重量份):
白芨45-55 百部55-65 牡蛎40-50
贝母28-32 阿胶28-32 甲珠40-50。
本发明具有治痨杀虫、滋阴降火、润肺止咳、益气健脾、清热化痰、生血、止血之功效,无毒无副作用及不良反应,对人体各脏器、肝、脑、肾、中枢神经无损害,治疗时间短,见效快,对肺部各型结核病治愈率高,愈后不易复发。
临床病例如下:
病例1:邹XX,男,44岁,症状:无力,午后低热、咳嗽、气短、胸痛、盗汗、消瘦,2002年5月9日经县医院胸片诊断,左上肺浸调型肺结核,结核抗体检验阳性,服本药品10天后,上述症状消失,体重增加,40天胸片复查,两片对比,病灶全部治愈,无钙化灶影,结核菌抗体检验阴性。
病例2:杨XX,男,38岁,症状:胸痛、咳嗽、呼吸困难,午后低热、无力、消瘦,两个月余,2002年2月3日,经哈医大胸片诊断,右上肺结核,左肺的淋巴结肿大,结核菌检验阳性,服用异烟肼、利福平、乙胺丁醇一个月,胸片检查未见好转,改肥本中药后,上述症状消失,三个疗程痊愈,胸片复查,三片对比,右肺门有钙化灶影,右上肺病灶消失,结核菌检验为阴性。
病例3:江XX,女,20岁,症状:咳嗽、无力、低烧,2001年9月,经哈医大胸片诊断,右上肺结核、结核菌抗体检验为阳性。服用利福平、异烟肼、利福喷丁、静注对氨基水杨酸钠、肌注硫酸链霉素,两个月后,胸片复查,两片对比,病灶未见明显吸收,因恶心、头痛、失眠、记忆力减退、耳鸣、肝功检验转氨酶升高而停药。服本中药两个疗程60天后,病情明显好转,经胸片复查,CT片对比,结核灶完全吸收钙化,病灶痊愈。
病例4:于XX,男,24岁,患两肺散在性浸润型肺结核,经多方住院治疗,病情不见好转,记忆力减退,肝功能异常。服用本中药后,病情明显好转,食欲增加,体重增加,肝功能检验正常。三个疗程胸片复查,肺内结核病灶吸收,并留下多个钙化灶影。
病例5:刘XX,女,46岁,患右上肺结核多年,经西药治疗效果不明显,放弃治疗,食欲不振,消瘦明显,服本药后,病情明显好转,食欲增加,体重增加6公斤,三个疗程后胸片检查,右上肺斑条状钙化灶影,痊愈。
本发明通过临床试验治疗肺结核患者共一千多例,治愈率高,效果好,用药时间短,对西药有抗药性的病人服用效果更好,总有效率达99%,显效率达98%,治愈率99%。
实施例
按下述配比称取原料(克)
白芨50 百部60 牡蛎45 贝母30 阿胶30 甲珠45。
将上述原料药洗干净,晾干后,研成粉末,混合均匀后装胶囊,即得。
Claims (2)
1、一种治疗肺结核病的中药,其特征在于:该药物是由下列重量份配比的原料药制成的:
白芨45-55 百部55-65 牡蛎40-50
贝母28-32 阿胶28-32 甲珠40一50
将上述原料药洗干净,晾干后,研成粉末,混合均匀后装胶囊,即得。
2、根据权利要求1所述的一种治疗肺结核病的中药,其特征在于:该药物是由下列重量份配比的原料药制成的:
白芨50 百部60 牡蛎45 贝母30 阿胶30 甲珠45
将上述原料药洗干净,晾干后,研成粉末,混合均匀后装胶囊,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031108938A CN1256137C (zh) | 2003-01-15 | 2003-01-15 | 一种治疗肺结核病的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031108938A CN1256137C (zh) | 2003-01-15 | 2003-01-15 | 一种治疗肺结核病的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1517112A CN1517112A (zh) | 2004-08-04 |
CN1256137C true CN1256137C (zh) | 2006-05-17 |
Family
ID=34283292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031108938A Expired - Fee Related CN1256137C (zh) | 2003-01-15 | 2003-01-15 | 一种治疗肺结核病的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1256137C (zh) |
-
2003
- 2003-01-15 CN CNB031108938A patent/CN1256137C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1517112A (zh) | 2004-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041341B (zh) | 用于治疗结核性渗出性胸膜炎的中药组合物及其制备方法 | |
CN102512627B (zh) | 一种用于肺癌术后的中药组合物 | |
CN101327313A (zh) | 治疗胃脘痛类的口服药物 | |
CN101085269B (zh) | 一种内服治疗肺癌的中药组合物 | |
CN104940485A (zh) | 一种治疗小儿哮喘的中药组合物及其制备方法 | |
CN104758762A (zh) | 一种治疗肺痨的中药组合物 | |
CN106963921A (zh) | 一种治疗乳腺增生的外用中药组合物及其制备方法 | |
CN106039109A (zh) | 防治寒湿阻络型的类风湿性关节炎的中药药酒 | |
CN103599455B (zh) | 一种用于祛斑的中药胶囊 | |
CN1256137C (zh) | 一种治疗肺结核病的中药 | |
CN101417100B (zh) | 一种治疗继发性肺结核的药物及制备方法 | |
CN1698736A (zh) | 治疗乳腺增生、预防乳腺癌的外用药 | |
CN102908607B (zh) | 用于治疗慢性单纯性鼻炎的外用中药及其制备方法 | |
CN104127827A (zh) | 一种治疗胆道结石症的中药制剂 | |
CN103948872B (zh) | 一种治疗银屑病关节炎的中药 | |
CN107335011A (zh) | 治疗癌性疼痛的外用中药复方制剂 | |
CN106138856A (zh) | 一种治疗经间期出血的新型中药组合物及制备方法 | |
CN104547831A (zh) | 甲状腺机能亢进患者益气养阴药酒及制备方法 | |
CN105168868A (zh) | 一种治疗甲状腺炎的中药及其制备方法 | |
CN105456648A (zh) | 一种复方五藤消痛贴 | |
CN105267779A (zh) | 一种治疗乳腺增生的中药组合物 | |
CN104998346A (zh) | 一种治疗痛经的腰带及其制备方法 | |
Chen et al. | Traditional Chinese Veterinary Medicine Treatment of Oral Peripheral Odontogenic Fibromas in a Dog. | |
CN102784317A (zh) | 一种治疗口疮的中药组合物 | |
CN103611116A (zh) | 一种用于治疗妊娠呕吐的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |